此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Using Virtual Reality to Teach Mindfulness to People With Migraine (MIRAGE)

2026年8月25日 更新者:Carolyn A. Bernstein、Brigham and Women's Hospital

Migraine Intervention Using Reality-Assisted Guided Experience

The aim of this clinical trial is to learn if people with migraine can learn a type of biobehavioral therapy called Acceptance and Commitment Therapy (ACT) by using a virtual reality headset. Researchers are studying if this type of mindfulness therapy helps to decrease migraine-related disability. Participants will be randomized to treatment as usual or active virtual reality groups for four weeks. Everyone will keep symptom diaries, complete surveys, attend two clinic visits, and have two blood draws.

研究概览

详细说明

This study is designed to evaluate the clinical utility of REACT NeuroVR in patients with episodic migraine who are already receiving stable CGRP monoclonal antibody therapy. By combining pharmacologic advances with digitally delivered psychological support, we aim to assess whether this integrated approach can further reduce headache frequency, improve migraine-specific quality of life, and reduce anticipatory anxiety. Additionally, we will explore changes in inflammatory biomarkers to examine potential physiologic correlates of intervention-related improvement.

Ultimately, this study addresses a critical gap in migraine care: the integration of effective, accessible behavioral health strategies into the treatment paradigm for patients who continue to experience burdensome symptoms despite preventive therapy.

1. Specific Aims and Objectives

Aim 1 (Pilot and Feasibility Study):

To evaluate the feasibility, acceptability, and usability of personalized Acceptance and Commitment Therapy (ACT) delivered via REACT NeuroVR. Focus groups with key stakeholders (patients, clinicians, and implementation experts) will be conducted to obtain feedback on intervention content, delivery, and outcome measures. Insights from this pilot phase will inform refinements to the intervention and study procedures for the subsequent full-scale clinical trial.

Aim 2 (Primary Efficacy Aim):

To determine whether personalized ACT therapy delivered via REACT NeuroVR reduces the number of monthly headache days in patients with episodic migraine compared to baseline.

Aim 3 (Psychological and Functional Outcomes):

To evaluate whether REACT NeuroVR improves migraine-specific quality of life and reduces anticipatory anxiety related to migraine events.

Aim 4 (Exploratory Biological and Sensory Aims):

To explore changes in inflammatory biomarkers.

Participants will:

Be randomized to treatment as usual or active VR participants Everyone who completes run-in will have a chance to try the VR device and have an additional screen.

Everyone will have a blood test at the beginning and the end of the study. Active participants will be loaned a VR device to take home for four weeks and will do the study activities as well as use a variety of experiences when they choose (such as beach visits, virtual ice baths and others) Participants will fill out surveys throughout the study.

Visit the clinic twice during the study Keep a diary of their symptoms and number of migraines

研究类型

介入性

注册 (估计的)

160

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02155
        • Brigham and Womens Hospital
      • Chestnut Hill、Massachusetts、美国、02467
        • Brigham and Women's Hospital
      • Chestnut Hill、Massachusetts、美国、02467
        • Brigham and Women's Health Care Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adults aged 18-80
  • Diagnosed with episodic migraine and experience 4-10 migraine days/month
  • On a stable dose of CGRP mAb for three months prior
  • Satisfy 4 week run-in of 4-10 headaches/month
  • Not taking other preventive medications
  • Not pregnant, breastfeeding, or planning to become pregnant within study timeframe
  • Able and willing to use VR device
  • No history of significant psychiatric illness
  • Willing to comply with study procedures
  • English-speaking

Exclusion Criteria:

  • Medication overuse (>10 days/month)
  • Vertigo/vestibular dysfunction
  • Active psychiatric or neurological comorbidities
  • Pregnancy, breastfeeding or planning pregnancy within study timeframe
  • Significant visual/hearing/mobility impairment affecting VR use

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
无干预:Treatment as usual
This group will remain on their CGRP injectable monoclonal antibody migraine preventive medication
有源比较器:Active Treatment
This group will participate in the four week active virtual reality treatment and will also remain on their CGRP mAb medication.
This is ACT/mindfulness therapy delivered via a virtual reality headset.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase one: Qualitative Interview of User Experience
大体时间:2 weeks
Assessment of user experience captured using open ended questions, yes/no questions, and a 4-point scale ranging from "Very Poor" to "Very Good".
2 weeks
Phase one: rate of participants using virtual reality for migraine-- qualitative data
大体时间:2 weeks
Assessment of how often and how long participants used the devices. Two 6-point scales included ranging from "Never" to "12-14 days" as well as "Under 10 minutes" to "More than 2 hours".
2 weeks
Phase two: Efficacy as described by number of headache days
大体时间:6 Months
6 Months

次要结果测量

结果测量
措施说明
大体时间
Phase two: Headache Disability Inventory
大体时间:6 Months
Assessment of acceptance and commitment (ACT) treatment on migraine-associated disability
6 Months
Phase two: Change in Inflammatory Biomarker panel-NULISAseq Inflammation 250
大体时间:baseline and 12 weeks
Will be measuring serum samples prior to study and at 12-week time to assess for change
baseline and 12 weeks
Anxiety and Depression
大体时间:baseline and 12 weeks
Migraine related anxiety and depression will be assessed by PROMIS29
baseline and 12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:carolyn bernstein, MD、BWH

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月24日

初级完成 (估计的)

2029年8月1日

研究完成 (估计的)

2031年1月1日

研究注册日期

首次提交

2026年4月28日

首先提交符合 QC 标准的

2026年5月14日

首次发布 (实际的)

2026年5月20日

研究记录更新

最后更新发布 (实际的)

2026年8月26日

上次提交的符合 QC 标准的更新

2026年8月25日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

We will share demographics including age and sex within the BWH researchers.

IPD 共享时间框架

current to completion of final publication, approximately five years

IPD 共享访问标准

Only BWH research team will have access to the IPD

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅